BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

904 related articles for article (PubMed ID: 33291863)

  • 1. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease.
    Jennison E; Byrne CD
    Clin Mol Hepatol; 2021 Jan; 27(1):22-43. PubMed ID: 33291863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.
    Quesada-Vázquez S; Aragonès G; Del Bas JM; Escoté X
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
    Bakhshimoghaddam F; Alizadeh M
    Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.
    Panasevich MR; Peppler WT; Oerther DB; Wright DC; Rector RS
    Physiol Genomics; 2017 Aug; 49(8):385-399. PubMed ID: 28600319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
    Safari Z; Gérard P
    Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.
    Aron-Wisnewsky J; Vigliotti C; Witjes J; Le P; Holleboom AG; Verheij J; Nieuwdorp M; Clément K
    Nat Rev Gastroenterol Hepatol; 2020 May; 17(5):279-297. PubMed ID: 32152478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOD2 in hepatocytes engages a liver-gut axis to protect against steatosis, fibrosis, and gut dysbiosis during fatty liver disease in mice.
    Cavallari JF; Pokrajac NT; Zlitni S; Foley KP; Henriksbo BD; Schertzer JD
    Am J Physiol Endocrinol Metab; 2020 Aug; 319(2):E305-E314. PubMed ID: 32516028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zuogui-Jiangtang-Qinggan-Fang alleviates high-fat diet-induced type 2 diabetes mellitus with non-alcoholic fatty liver disease by modulating gut microbiome-metabolites-short chain fatty acid composition.
    Zou J; Xiang Q; Tan D; Shi L; Liu X; Wu Y; Yu R
    Biomed Pharmacother; 2023 Jan; 157():114002. PubMed ID: 36410120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diet and gut microbiome in fatty liver and its associated liver cancer.
    Pan Y; Zhang X
    J Gastroenterol Hepatol; 2022 Jan; 37(1):7-14. PubMed ID: 34664301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Western diet-induced mouse model of non-alcoholic fatty liver disease associated with metabolic outcomes: Features of gut microbiome-liver-adipose tissue axis.
    Romualdo GR; Valente LC; Sprocatti AC; Bacil GP; de Souza IP; Rodrigues J; Rodrigues MAM; Vinken M; Cogliati B; Barbisan LF
    Nutrition; 2022; 103-104():111836. PubMed ID: 36202025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the gut microbiota in NAFLD.
    Leung C; Rivera L; Furness JB; Angus PW
    Nat Rev Gastroenterol Hepatol; 2016 Jul; 13(7):412-25. PubMed ID: 27273168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome.
    Abenavoli L; Scarlata GGM; Scarpellini E; Boccuto L; Spagnuolo R; Tilocca B; Roncada P; Luzza F
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unveiling the role of gut dysbiosis in non-alcoholic fatty liver disease.
    Jadhav PA; Thomas AB; Nanda RK; Chitlange SS
    Eur J Gastroenterol Hepatol; 2023 Dec; 35(12):1324-1333. PubMed ID: 37823422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
    Jayachandran M; Qu S
    Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal Microbiota in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: A Systematic Review.
    Mohammadi Z; Poustchi H; Motamed-Gorji N; Eghtesad S; Hekmatdoost A; Saniee P; Merat S
    Arch Iran Med; 2020 Jan; 23(1):44-52. PubMed ID: 31910634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota and non-alcoholic fatty liver disease.
    Gkolfakis P; Dimitriadis G; Triantafyllou K
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease.
    Jacob JS; Ahmed A; Cholankeril G
    Curr Opin Infect Dis; 2021 Oct; 34(5):477-482. PubMed ID: 34267042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.